- 4-Week # shares sold: 750
- 12-Week # shares bought: 1,000
- 12-Week # shares sold: 1,500
- 24-Week # shares bought: 1,500
- 24-Week # shares sold: 8,750
House Democrats start probe into MS drug prices
'Biogen has a relatively under-leverage balance sheet, and we expect [free cash flow yield] and US cash to grow.'
All eyes are on Pfizer in the months ahead.